EA201990565A1 - Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид - Google Patents

Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид

Info

Publication number
EA201990565A1
EA201990565A1 EA201990565A EA201990565A EA201990565A1 EA 201990565 A1 EA201990565 A1 EA 201990565A1 EA 201990565 A EA201990565 A EA 201990565A EA 201990565 A EA201990565 A EA 201990565A EA 201990565 A1 EA201990565 A1 EA 201990565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline
displaced
pyrazolyl steroid
steroid
pyrazolyl
Prior art date
Application number
EA201990565A
Other languages
English (en)
Inventor
Пол Стивен Уотсон
Брет Бернер
Джон Грегори Рид
Цзянь ВАН
Джеймс Доуэрти
Стефен Джей Кейнз
Original Assignee
Сейдж Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейдж Терапьютикс, Инк. filed Critical Сейдж Терапьютикс, Инк.
Publication of EA201990565A1 publication Critical patent/EA201990565A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Изобретение относится к 19-нор C3,3-дизамещенному C21-пиразолил стероиду формулы (I)и его кристаллической твердой форме и композиции. Также в настоящем документе описаны способы получения кристаллической твердой формы 19-нор C3,3-дизамещенного C21-пиразолил стероида формулы (I) и способы применения 19-нор C3,3-дизамещенного C21-пиразолил стероида формулы (I) или кристаллической твердой формы, его фармацевтически приемлемых солей и фармацевтически приемлемой композиции.
EA201990565A 2016-08-23 2017-08-23 Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид EA201990565A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378582P 2016-08-23 2016-08-23
PCT/US2017/048267 WO2018039378A1 (en) 2016-08-23 2017-08-23 A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid

Publications (1)

Publication Number Publication Date
EA201990565A1 true EA201990565A1 (ru) 2019-07-31

Family

ID=59772778

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990565A EA201990565A1 (ru) 2016-08-23 2017-08-23 Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид

Country Status (23)

Country Link
US (3) US11236121B2 (ru)
EP (2) EP3504189A1 (ru)
JP (2) JP2019524853A (ru)
KR (2) KR20230079470A (ru)
CN (4) CN115974954A (ru)
AR (3) AR109393A1 (ru)
AU (3) AU2017315682B2 (ru)
BR (1) BR112019003637A2 (ru)
CA (1) CA3034262A1 (ru)
CL (2) CL2019000477A1 (ru)
CO (1) CO2019002596A2 (ru)
EA (1) EA201990565A1 (ru)
EC (1) ECSP19020141A (ru)
IL (1) IL302480A (ru)
JO (1) JOP20190022B1 (ru)
MA (1) MA46042A (ru)
MX (2) MX2019002193A (ru)
PE (1) PE20190915A1 (ru)
PH (1) PH12019500375A1 (ru)
SG (1) SG11201901445TA (ru)
TW (2) TW202342059A (ru)
WO (1) WO2018039378A1 (ru)
ZA (1) ZA201901051B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
SG11201508550XA (en) 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
PL3206493T3 (pl) 2014-10-16 2021-01-25 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
IL302480A (en) 2016-08-23 2023-06-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
TW202342058A (zh) * 2017-09-07 2023-11-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
CA3075872A1 (en) * 2017-09-14 2019-03-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN117959309A (zh) * 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
MA54594A (fr) 2018-12-05 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et leurs procédés d'utilisation
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
US20220098230A1 (en) * 2019-01-31 2022-03-31 Shenzhen Rentai Pharmatech Ltd. y-AMINOBUTYRIC ACID MODULATOR CRYSTAL FORM X, PREPARATION METHOD AND APPLICATION THEREOF
WO2020242772A1 (en) 2019-05-28 2020-12-03 Teva Czech Industries S.R.O Solid state forms of sage-217 and processes for preparation thereof
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
KR20220066262A (ko) * 2019-08-07 2022-05-24 상하이 한서 바이오메디컬 컴퍼니 리미티드 스테로이드 유도체 조절제의 염 및 결정형
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
BR112023000990A2 (pt) 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
US20240122945A1 (en) 2021-01-28 2024-04-18 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
JP2024510436A (ja) 2021-03-17 2024-03-07 セージ セラピューティクス， インコーポレイテッド 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド
JP2024515830A (ja) 2021-04-29 2024-04-10 セージ セラピューティクス， インコーポレイテッド 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド
KR20240006026A (ko) 2021-04-29 2024-01-12 세이지 테라퓨틱스, 인크. 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
BR112024001518A2 (pt) 2021-07-28 2024-04-30 Sage Therapeutics Inc Formas cristalinas de um esteroide neuroativo
WO2023158668A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023163879A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
EP1481969B1 (en) 2002-02-08 2011-01-19 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
JP2014521662A (ja) 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
RU2663665C2 (ru) 2012-12-18 2018-08-08 Вашингтон Юниверсити Нейроактивные 19-алкокси-17-замещенные стероиды и способы лечения с их применением
SG11201508550XA (en) 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PL3206493T3 (pl) * 2014-10-16 2021-01-25 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
AU2016321254A1 (en) 2015-09-08 2018-04-05 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
WO2017087864A1 (en) 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
IL302480A (en) 2016-08-23 2023-06-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CN116370475A (zh) 2017-08-31 2023-07-04 武田药品工业株式会社 中枢神经系统病症的治疗
TW202342058A (zh) 2017-09-07 2023-11-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
CA3075872A1 (en) 2017-09-14 2019-03-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
SG11202004329TA (en) 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AU2018388408B2 (en) 2017-12-22 2023-12-21 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CA3086189A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2019140272A1 (en) 2018-01-12 2019-07-18 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
CN117959309A (zh) 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
EP3864022B1 (en) 2018-10-12 2023-09-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
JP2022505146A (ja) 2018-10-19 2022-01-14 セージ セラピューティクス， インコーポレイテッド ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
MA54594A (fr) 2018-12-05 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et leurs procédés d'utilisation
WO2020132504A1 (en) 2018-12-21 2020-06-25 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
TW202110824A (zh) 2019-05-24 2021-03-16 美商賽吉醫療公司 化合物、組合物及使用方法
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
AU2020395246A1 (en) 2019-12-05 2022-06-16 Sage Therapeutics, Inc. A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
IL296371A (en) 2020-03-18 2022-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
BR112023000990A2 (pt) 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas

Also Published As

Publication number Publication date
BR112019003637A2 (pt) 2019-08-06
AU2022200811A1 (en) 2022-02-24
US20230399357A1 (en) 2023-12-14
CN110088091A (zh) 2019-08-02
WO2018039378A1 (en) 2018-03-01
CL2019003610A1 (es) 2020-05-22
AU2017315682A2 (en) 2019-04-18
US11884696B2 (en) 2024-01-30
AU2022200811B2 (en) 2023-12-21
PE20190915A1 (es) 2019-06-26
TWI808945B (zh) 2023-07-21
AR125320A2 (es) 2023-07-05
JP2023002846A (ja) 2023-01-10
SG11201901445TA (en) 2019-03-28
ZA201901051B (en) 2020-12-23
CN115974954A (zh) 2023-04-18
MX2019002193A (es) 2019-10-07
EP3981763A1 (en) 2022-04-13
MX2022007432A (es) 2022-07-19
PH12019500375A1 (en) 2019-06-17
AR125321A2 (es) 2023-07-05
CL2019000477A1 (es) 2019-06-21
KR20190040043A (ko) 2019-04-16
JOP20190022A1 (ar) 2019-02-18
US20220169674A1 (en) 2022-06-02
MA46042A (fr) 2019-07-03
IL302480A (en) 2023-06-01
AU2022200811B9 (en) 2024-01-04
CO2019002596A2 (es) 2019-03-29
CN115974956A (zh) 2023-04-18
AU2017315682B2 (en) 2021-11-11
CN115974955A (zh) 2023-04-18
TW201808982A (zh) 2018-03-16
US11236121B2 (en) 2022-02-01
JOP20190022B1 (ar) 2023-03-28
AU2017315682A1 (en) 2019-03-07
AR109393A1 (es) 2018-11-28
EP3504189A1 (en) 2019-07-03
US20190177359A1 (en) 2019-06-13
KR20230079470A (ko) 2023-06-07
JP2019524853A (ja) 2019-09-05
AU2024200732A1 (en) 2024-02-22
TW202342059A (zh) 2023-11-01
ECSP19020141A (es) 2019-04-30
CA3034262A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
MX2020004504A (es) Derivados de fenoximetilo.
PH12018500777A1 (en) Farnesoid x receptor modulators
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
MX2020007265A (es) Derivados de rapamicina.
EA201691302A1 (ru) Новые гетероциклические соединения
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2019015744A (es) Composiciones farmaceuticas.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
MX2021006697A (es) Composición y método para el crecimiento del cabello.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2016011992A (es) Derivados de piperidina-diona.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
CY1125355T1 (el) Πεντακυκλικη ενωση
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов